# Chronic Obstructive Pulmonary Disease

## Medication  

|| Class |
| --- | --- |
| SAMA | Short Acting Anticholinergics/Muscarinic Antagnists |
| LAMA | Long Acting Anticholinergics/Muscarinic Antagnists |
| SABA | Short Acting Beta<sub>2</sub>-Antagonists |
| LABA | Long Acting Beta<sub>2</sub>-Antagonists |
| ICS | Inhaled Corticosteroids |
| SCS | Systemic Corticosteroids |
| PDE4-Inhibitor | Phosphodiesterase-4-Inhibitors |
|| Methylxanthine|

#### Information

- SAMA/SABA — ↑ FEV<small>1</small> and Symptoms
- Combination SAMA + SABA is better than Monotherapy
- LAMA/LABA — ↑ Lung Function, Dyspnea + ↓ Exacerbation Rates
- Combination LAMA + LABA is better than Monotherapy
- Tioproprium — ↑ Pulmonary Rehabilitation by ↑ Exercise Capacity
- Combination ICS + LABA is better than Monotherapy in ↑ Lung Function, Health Status + ↓ Exacerbation in Moderate and Severe COPD
- Long Term ICS Use — ↑ Risk of Pneumonia
- Triple Therapy ICS + LABA + LAMA is better than Dual Therapy
- PDE4-Inhibitors — ↑ Lung Function + ↓ in Moderate and Severe Exacerbation in patients with Chronic Bronchitis as well as Severe COPD

### Dosier-Aerosol (MDI), Powder Inhalation (DPI) and Soft Mist Inhalfer (SMI)

| Class | Medication | Type | Dose | Duration |
| --- | --- | --- | --- | --- |
| SAMA | Ipratropiumbromid | MDI | 20 µg | 6 – 8 Hours
| LAMA | Aclinidium | DPI | 322 µg | 12 Hours |
| – &middot;&middot; – | Glycopyrronium | DPI | 44 µg | 24 Hours |
| – &middot;&middot; – | Tioproprium | DPI<br>SMI | 18 µg<br>2.5 µg | 24 Hours |
| – &middot;&middot; – | Umeclidinium | DPI | 55 µg | 24 Hours |
| SABA | Fenoterolhydrobromid | MDI | 100 µg | 4 – 6 Hours |
| – &middot;&middot; – | Salbutamol | DPI<br>MDI | 90 – 200 µg<br>90 – 180 µg | 4 – 6 Hours |
| – &middot;&middot; – | Terbutalinsulfat| DPI | 500 µg | 4 – 6 Hours |
| LABA | Formoterolfumarat-Dihydrat | MDI | 10 µg<br>5.1 – 10.2 µg | 12 Hours |
| – &middot;&middot; – | Indacaterol | DPI | 120 – 240 µg | 24 Hours |
| – &middot;&middot; – | Olodaterolhydrochlorid | SMI | 2.5 µg | 24 Hours |
| – &middot;&middot; – | Salmeterol | MDI<br>DPI | 21 µg<br>50 µg | 12 Hours |
| SAMA + SABA<br><small>Combination</small> | Ipratropiumbromid + Fenoterolhydrobromid | MDI<br>SMI | 20/50 µg<br>20/50 µg | 6 – 8 Hours |
| LAMA + LABA<br><small>Combination</small> | Aclidium + Formoterolfumaratdihydrat | DPI | 340/11.8 µg | 12 Hours |
| – &middot;&middot; – | Indacaterol + Glycopyrronium | DPI | 85/43 µg | 24 Hours |
| – &middot;&middot; – | Umeclidium + Vilanterol | DPI | 55/22 µg | 24 Hours |
| – &middot;&middot; – | Tiotropium + Olodaterol | SMI | 2.5/2.5 µg | 24 Hours |
| ICS | Beclometasondipropionat  | MDI | 100 – 250 µg | ... |
| – &middot;&middot; – | Budesonid | MDI<br>DPI | 184 µg<br>200 – 400 µg | ... |
| – &middot;&middot; – | Fluticasonpropionat | MDI<br>DPI | 220 µg<br>250 – 500 µg | ... |
| LABA + ICS<br><small>Combination</small> | Beclometasondipropionat + Formoterolfumaratdihydrat | MDI | 84.6/5 µg | 12 Hours |
| – &middot;&middot; – | Budesonid + Formoterolhemifumarat | DPI | 160 – 320/4.5 – 9 µg | 12 – 24 Hours |
| – &middot;&middot; – | Salmeterol + Fluticasonpropionat | DPI | 47 – 92/231 – 460 µg | ... |
| – &middot;&middot; – | Fluticasonfuroat + Vilanterol | DPI | 92 – 184/ 22 µg | 24 Hours |

### Nebuliser

| Class | Medication | Dose | Duration |
| --- | --- | --- | --- |
| SAMA | Ipratropiumbromid | 0.125 – 0.25 mg/mL | 6 – 8 Hours |
| SABA | Salbutamol | 0.5 mg/mL | 4 – 6 Hours |
| SAMA + SABA<br><small>Combination</small> | Ipratropiumbromid + Fenoterolhydrobromid | 0.25/0.5 mg/mL | 6 – 8 Hours |
| ICS | Beclometasondipropionat | 400 mg/mL | ... |
| – &middot;&middot; – | Budesonid | 500 – 1000 mg/mL | ... |

### Tablets

| Class | Medication | Dose | Duration |
| --- | --- | --- | --- |
| SABA | Terbutalinsulfat | 7.5 mg | 4 – 6 Hours |
| SCS | Prednisolon | 1 – 50 mg | ... |
| - &middot;&middot; – | Methylprednisolon | 4 – 32 mg | ... |
| Methylxanthine | Aminophyllin | 200 – 600 mg | up to 24 Hours |
| - &middot;&middot; – | Theophyllin | 125 – 500 mg | up to 24 Hours |

### Intavenous

| Class | Medication | Dose | Duration |
| --- | --- | --- | --- |
| SABA | Reproterolhydrochlorid | 0.09 mg/mL | ... |
| - &middot;&middot; – | Terbutalinsulfat | 0.5 mg/mL | 4 – 6 Hours |
| Methylxanthine | Theophyllin | 10 mL Vial has 200 mg Theophyllin | up to 24 Hours |

## Therapy

| Symptoms | Therapy |
| --- | --- |
| GOLD Group A | No Therapy<br><small>__OR__</small><br>SABA + SAMA<br><small>__OR__</small><br>LABA/LAMA |
| GOLD Group B | LABA/LAMA<br><small>__OR__</small><br>LABA + LAMA
| GOLD Group C/D<br><small>Not Previously Treated</small> | LAMA<br><small>__OR__</small><br>LAMA + LABA
| GOLD Group C/D<br><small>Previously Treated</small> | LAMA + LABA |
| Escalation/Change | LABA + ICS<br><small>__OR__</small><br>LAMA + LABA + ICS |
| Severe<br><small>chronic Bronchitis Type</small> | ± Roflumilast |